Kenneth Kolinsky
Overview
Explore the profile of Kenneth Kolinsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
1168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu J, Higgins B, Ju G, Kolinsky K, Luk K, Packman K, et al.
ACS Med Chem Lett
. 2014 Jun;
4(2):259-63.
PMID: 24900658
A new series of 7,8-disubstituted pyrazolobenzodiazepines based on the lead compound 1 have been synthesized and evaluated for their effects on mitosis and angiogenesis. Described herein is the design, synthesis,...
2.
Higgins B, Glenn K, Walz A, Tovar C, Filipovic Z, Hussain S, et al.
Clin Cancer Res
. 2014 May;
20(14):3742-52.
PMID: 24812409
Purpose: Antitumor clinical activity has been demonstrated for the MDM2 antagonist RG7112, but patient tolerability for the necessary daily dosing was poor. Here, utilizing RG7388, a second-generation nutlin with superior...
3.
Tovar C, Graves B, Packman K, Filipovic Z, Higgins B, Xia M, et al.
Cancer Res
. 2013 Feb;
73(8):2587-97.
PMID: 23400593
MDM2 negatively regulates p53 stability and many human tumors overproduce MDM2 as a mechanism to restrict p53 function. Thus, inhibitors of p53-MDM2 binding that can reactivate p53 in cancer cells...
4.
Su F, Bradley W, Wang Q, Yang H, Xu L, Higgins B, et al.
Cancer Res
. 2011 Dec;
72(4):969-78.
PMID: 22205714
A high percentage of patients with BRAF(V600E) mutant melanomas respond to the selective RAF inhibitor vemurafenib (RG7204, PLX4032) but resistance eventually emerges. To better understand the mechanisms of resistance, we...
5.
Yang H, Higgins B, Kolinsky K, Packman K, Bradley W, Lee R, et al.
Cancer Res
. 2011 Dec;
72(3):779-89.
PMID: 22180495
The protein kinase BRAF is a key component of the RAS-RAF signaling pathway which plays an important role in regulating cell proliferation, differentiation, and survival. Mutations in BRAF at codon...
6.
Kolinsky K, Tovar C, Zhang Y, Railkar A, Yang H, Carvajal D, et al.
Cancer Chemother Pharmacol
. 2011 May;
68(6):1585-94.
PMID: 21553286
Purpose: This study describes the antiproliferative activity of the multikinase inhibitor R1530 in vitro and its antitumor and anti-angiogenic activity, pharmacokinetics, and tolerability in vivo. Methods: The antiproliferative activity of...
7.
Tovar C, Higgins B, Kolinsky K, Xia M, Packman K, Heimbrook D, et al.
Mol Cancer
. 2011 May;
10:49.
PMID: 21539745
Background: Hormone therapy is the standard of care for newly diagnosed or recurrent prostate cancers. It uses anti-androgen agents, castration, or both to eliminate cancer promoting effect of testicular androgen....
8.
He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X, et al.
Mol Oncol
. 2011 Feb;
5(3):292-301.
PMID: 21315665
Interest continues to build around the early application of patient selection markers to prospectively identify patients likely to show clinical benefit from cancer therapies. Hypothesis generation and clinical strategies often...
9.
Liu J, Daniewski I, Ding Q, Higgins B, Ju G, Kolinsky K, et al.
Bioorg Med Chem Lett
. 2010 Sep;
20(20):5984-7.
PMID: 20832307
A novel series of pyrazolobenzodiazepines 3 has been identified as potent inhibitors of cyclin-dependent kinase 2 (CDK2). Their synthesis and structure-activity relationships (SAR) are described. Representative compounds from this class...
10.
Tovar C, Higgins B, Deo D, Kolinsky K, Liu J, Heimbrook D, et al.
Cell Cycle
. 2010 Sep;
9(16):3364-75.
PMID: 20814247
Polyploidy results from deregulated cell division and has been considered an undesirable event leading to increased mutation rate and cancer development. However, polyploidy may also render cancer cells more vulnerable...